1-methyl-3-ethyl-2,5-imidazolidinedione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 1-methyl-3-ethyl-2,5-imidazolidinedione
• 英文别名: 1-ethyl-3-methyl-imidazolidine-2,4-dione；1-Aethyl-3-methyl-imidazolidin-2,4-dion；1-Ethyl-3-methylimidazolidine-2,4-dione
• 化学式: C₆H₁₀N₂O₂
• 分子量: 142.158
• InChiKey: ZRJSUQHHXOCGFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-甲基甲酰胺 、 N-乙基乙醇胺 在 [RuH(tBu-PNP(-))(CO)] 作用下， 以 乙二醇二乙醚 为溶剂， 反应 16.0h， 以78%的产率得到1-methyl-3-ethyl-2,5-imidazolidinedione
  参考文献：
  名称：

  甲酰胺作为异氰酸酯替代物：一种开发原子效率、选择性催化合成尿素、氨基甲酸酯和杂环的机械驱动方法

  摘要：

  尽管异氰酸酯具有危险性，但它们仍然是散装和精细化学品合成的关键组成部分。通过用效力较低且易于获得的甲酰胺前体替代它们，我们在此展示了一种替代的机械方法，通过基于钌的钳形复合物催化的无受体脱氢偶联反应选择性地获得广泛的尿素、氨基甲酸酯和杂环。这些高原子效率程序的设计是由相关有机金属配合物的鉴定和表征驱动的，独特地表现出异氰酸酯中间体的捕获。DFT 计算进一步有助于阐明催化事件的精心编排链，涉及金属-配体合作。

  DOI：

  10.1021/jacs.9b08942

文献信息

• UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF
  申请人：RAPT THERAPEUTICS, INC.

  公开号：US20210317134A1

  公开（公告）日：2021-10-14

  Disclosed herein, inter alia, compounds and methods of use thereof for the modulation of USP7 activity.

  本公开的内容包括化合物及其使用方法，用于调节USP7活性。
• α-Ureidoalkylation of thiosemicarbazide and aminoguanidine
  作者：A. S. Sigachev、A. N. Kravchenko、P. A. Belyakov、O. V. Lebedev、N. N. Makhova

  DOI：10.1007/s11172-006-0344-6

  日期：2006.5

  azo[4,5-e][1,2,4]triazin-6-ones, 4,5-bis(3-thiosemicarbazido(guanidinoamino))imidazolidin-2-ones, and 1,3-dialkyl-4-(guanidinoimino)imidazolidin-2-ones by α-ureidoalkylation of thiosemicarbazide or aminoguanidine were found. A novel conglomerate in the series of imidazolidin-2-one derivatives was detected: 4,5-bis(guanidinoamino)-1,3-dimethylimid-azolidin-2-one dihydrochloride dihydrate.

  通过硫代氨基脲或氨基胍的 α-ureido 烷基化作用，发现了偶氮[4,5-e][1,2,4]三嗪-6-酮、4,5-双（3-硫代氨基脲（胍基氨基））咪唑烷-2-酮和 1,3-二烷基-4-（胍基氨基）咪唑烷-2-酮。在咪唑烷-2-酮衍生物系列中发现了一种新的集合体：4,5-双（胍基氨基）-1,3-二甲基咪唑烷-2-酮二盐酸盐二水合物。
• ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
  申请人：——

  公开号：US20030166687A1

  公开（公告）日：2003-09-04

  The present invention provides a compound of formula (1), or pharmaceutical acceptable salts thereof wherein R1 is C4-12 alkyl, C4-12 alkenyl, C4-12 alkynyl, —(CH2)h-C3-8 cycloalkyl, substituted and unsubstituted —(CH2)h-aryl, substituted and unsubstituted-(CH2)h-het, R2 is substituted and unsubstituted C1-12 alkyl, substituted and unsubstituted C2-12 alkenyl, substituted and unsubstituted C2-12 alkynyl, substituted and unsubstituted-(CH2)h-C3-8 cycloakyl, substituted and unsubstituted —(CH2)h-C3-8 unsubstituted-(CH2)h-C3-8 cycloakyl, substituted and unsubstituted —(CH2)h-C3-8 cycloalkenyl, substituted and unsubstituted-(CH2)h-aryl, substituted and unsubstituted-(CH2)h-heterocyclic ring, substituted and unsubstituted —(CH2)i-X—R4 (X is —O—, —S(═O)j-, —NR7-, —S(═O)2NR8-, or —C(═O)—), and —(CH2)iCHR5R6. The compounds are inhibitors of matrix metalloproteinases involved in tissue degradation

  本发明提供了一种化合物，其化学式为（1），或其药物可接受的盐，其中R1为C4-12烷基，C4-12烯基，C4-12炔基，-(CH2)h-C3-8环烷基，取代和未取代的-(CH2)h-芳基，取代和未取代的-(CH2)h-杂环基，R2为取代和未取代的C1-12烷基，取代和未取代的C2-12烯基，取代和未取代的C2-12炔基，取代和未取代的-(CH2)h-C3-8环烷基，取代和未取代的-(CH2)h-C3-8未取代的-(CH2)h-C3-8环烷基，取代和未取代的-(CH2)h-C3-8环烯基，取代和未取代的-(CH2)h-芳基，取代和未取代的-(CH2)h-杂环环，取代和未取代的-(CH2)i-X-R4（X为—O—，—S(═O)j-，—NR7-，—S(═O)2NR8-，或—C(═O)—），以及-(CH2)iCHR5R6。这些化合物是参与组织降解的基质金属蛋白酶的抑制剂。
• c-MET MODULATORS AND METHOD OF USE
  申请人：BANNEN CANNE LYNNE

  公开号：US20070244116A1

  公开（公告）日：2007-10-18

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

  本发明提供了用于调节蛋白激酶酶活性，以调节细胞活动，如增殖、分化、程序性细胞死亡、迁移和化学侵袭的化合物。更具体地，本发明提供了喹唑啉和喹啉，这些化合物抑制、调节和/或调节激酶受体，特别是c-Met、KDF、c-Kit、flt-3和flt-4，与上述细胞活动变化相关的信号转导途径，包含这些化合物的组合物，以及使用它们治疗激酶依赖性疾病和病况的方法。本发明还提供制备上述化合物的方法和包含这些化合物的组合物。
• DIHYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES
  申请人：Dasseux Jean-Louis Henri

  公开号：US20090247489A1

  公开（公告）日：2009-10-01

  The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型二羟基化合物、包含羟基化合物的组合物，以及用于治疗和预防各种疾病和病症的方法，例如但不限于老化、阿尔茨海默病、癌症、心血管疾病、糖尿病肾病、糖尿病视网膜病变、葡萄糖代谢紊乱、血脂异常、高血压、阳痿、炎症、胰腺炎、帕金森病、过氧化物酶体增殖物激活受体相关疾病、胆汁中脂质消除、肥胖症、胆汁中氧化固醇消除、肾脏疾病、败血症、代谢综合症（例如综合征X）、血栓性疾病等。本发明的化合物和方法还可用于调节C反应蛋白或增强患者的胆汁产生。在某些实施例中，本发明的化合物、组合物和方法可与其他治疗剂（如降胆固醇和降血糖药物）结合使用。